Is Brukinsa (Zanubrutinib) a Safer Bruton’s Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis

<b>Background/Objectives:</b> Zanubrutinib (Brukinsa) is a next-generation Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); however, a comprehensive quantitative assessment of its sa...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Helal F. Hetta, Ayman Salama, Turki A. Aljuaid, Yazan T. Mojmami, Riyadh S. Alotibi, Ahmed M. Alqabaly, Nawaf A. Aldosari, Sami A. Alshahri, Walid I. A. Asiri, Raed S. Alamri, Fayez A. Alanazi, Malek S. A. Alenazi, Mohammed H. Albuhayri, Yasmin N. Ramadan, Reem Sayad
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2026-03-01
Schriftenreihe:	Pharmaceuticals
Schlagworte:	zanubrutinib BGB-3111 Bruton’s tyrosine kinase inhibitor chronic lymphocytic leukemia Brukinsa small lymphocytic lymphoma
Online-Zugang:	https://www.mdpi.com/1424-8247/19/3/467
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!